PLZM_LAB
KO EN
ANTI-INFLAMMATORY WHITENING ANTI-AGING

Reduced inflammatory response

In human keratinocytes (HaCaT) and a BALB/c atopic dermatitis mouse model, PAW treatment eased skin inflammation and reduced inflammatory cytokine expression.

Improved skin inflammation

Significant cytokine
reduction

Anti-inflammatory effect similar to dexamethasone

Improved skin barrier

See the cell-based results using human keratinocytes (HaCaT).

See the results from the BALB/c atopic dermatitis mouse model.
02

ATOPIC DERMATITIS MODEL

Skin improvement in the atopic dermatitis model

PAW treatment eased visible skin inflammation and histological changes.

Animal model  in vivo

BALB/c (Atopic Dermatitis mouse model)

Representative ear images

Con
AD
AD +
PAW 100 ppm
AD +
PAW 500 ppm
AD +
PAW 1000 ppm
AD +
Dexa 2 mg/kg

Cytokine expression (qPCR)

Tnf-α

Il-1β

Il-4

Ccl17

Data are mean ± SD (n=3). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. AD.

Histological analysis
01

INFLAMMATORY SIGNALING

Reduced inflammatory cytokine expression

PAW treatment significantly reduced expression of key inflammatory cytokines related to atopic dermatitis.

Cell model  in vitro

HaCaT (human keratinocyte)

Skin barrier markers

FLG

TNF-α+IFN-γ100 %
PAW+ 100 ppm361.3 %
PAW+ 500 ppm389.1 %
PAW+ 1,000 ppm358.8 %

IVL

TNF-α+IFN-γ100 %
PAW+ 100 ppm367.2 %
PAW+ 500 ppm246.2 %
PAW+ 1,000 ppm265.1 %

LOR

TNF-α+IFN-γ100 %
PAW+ 100 ppm150.2 %
PAW+ 500 ppm277.7 %
PAW+ 1,000 ppm570.9 %

Inflammatory cytokines

TNF-α

TNF-α+IFN-γ100 %
PAW+ 100 ppm53.8 %
PAW+ 500 ppm56.4 %
PAW+ 1,000 ppm63.7 %

IL-1β

TNF-α+IFN-γ100 %
PAW+ 100 ppm23.5 %
PAW+ 500 ppm26.1 %
PAW+ 1,000 ppm29.5 %

IL-6

TNF-α+IFN-γ100 %
PAW+ 100 ppm25.9 %
PAW+ 500 ppm17.6 %
PAW+ 1,000 ppm18.8 %

IL-8

TNF-α+IFN-γ100 %
PAW+ 100 ppm48.6 %
PAW+ 500 ppm58.2 %
PAW+ 1,000 ppm37.1 %

Data are mean ± SD (n=3). *** p < 0.001 vs. TNF-α + IFN-γ.